DGAP-News: 4SC AG: 4 upcoming conferences
DGAP-News: 4SC AG / Key word(s): Conference
4SC AG: 4 upcoming conferences
Planegg-Martinsried, Germany, 16 May 2019 - 4SC AG (4SC, FSE Prime Standard: VSC) today announced its participation in upcoming financial and scientific conferences. 4SC's management and scientists will be available for one-on-one meetings at these events.
Passende neue Barrier Reverse Convertibles
20 - 21 May 2019
31 May - 4 June 2019
Raymond James Life Sciences and MedTech Conference
18 - 19 June 2019
20 - 21 June 2019
- Announcement ends -
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC's pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat.
4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.
4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 47 employees as of 31 March 2019 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).
Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC's control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
16.05.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
|Phone:||+49 89 700763-0|
|Fax:||+49 89 700763-29|
|Listed:||Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||811759|
|End of News||DGAP News Service|
Nachrichten zu 4SC AGmehr Nachrichten
||DGAP-Adhoc: 4SC AG gibt Bezugspreis für neue Aktien aus der laufenden Kapitalmassnahme bekannt (EQS Group)|
||DGAP-Adhoc: 4SC AG announces subscription price for new shares from current capital increase (EQS Group)|
||DGAP-Adhoc: 4SC AG resolves to issue new shares to continue to advance its drug development programs for resminostat and domatinostat (EQS Group)|
||DGAP-Adhoc: 4SC AG beschliesst Ausgabe neuer Aktien, um die Entwicklung der Medikamente Resminostat und Domatinostat weiter voranzubringen (EQS Group)|
||DGAP-News: 4SC AG: 4 anstehende Konferenzen (EQS Group)|
||DGAP-News: 4SC AG: 4 upcoming conferences (EQS Group)|
||DGAP-News: 4SC informiert über Q1 2019 (EQS Group)|
||DGAP-News: 4SC provides Q1 2019 update (EQS Group)|